Expanded Clinical Validation & Commercial Launch of the UriSeq Platform for Bladder Cancer

膀胱癌是第五大流行癌症，有超过70万人患有膀胱癌。 疾病在美国。这种疾病有一个特别高的病人负担，因为它在70%的复发， 患者接受初步治疗后。超过一半的患者没有反应或进展， 接受治疗或监视患者需要新的治疗和诊断选择 接受诊断和复发监测。 该项目支持UriSeq的持续技术和临床开发， 膀胱癌的诊断测试。该项目将支持扩大临床 有效性、临床实用性和卫生经济学对超过3,000例纵向监测膀胱 癌症患者。

Bladder cancer is the 5th most prevalent cancer with over 700,000 people living with the disease in the US. The disease has a particularly high patient burden as it recurs in 70% of patients following initial treatment. Over half of these patients do not respond or progress while on treatment or surveillance. New therapeutic and diagnostic options are needed for patients undergoing diagnosis and recurrence surveillance. This project is supporting the continued technical and clinical development of UriSeq, a diagnostic test for bladder cancer. This project will support development of expanded clinical validity, clinical utility and health economics on over 3,000 longitudinally monitored bladder cancer patients.